A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer

被引：0
|
作者：
I M E Desar
J N H Timmer-Bonte
D M Burger
W T A van der Graaf
C M L van Herpen
机构：
[1] Radboud University Nijmegen Medical Centre,Department of Medical Oncology 452
[2] Radboud University Nijmegen Medical Centre,Department of Clinical Pharmacy
来源：
British Journal of Cancer | 2010年 / 103卷
关键词：
phase I; sorafenib; sirolimus; tyrosine kinase inhibitor; mTOR inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1637 / 1643
页数：6
相关论文
共 50 条
  • [21] A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors
    Jameson, Gayle S.
    Hamm, John T.
    Weiss, Glen J.
    Alemany, Carlos
    Anthony, Stephen
    Basche, Michele
    Ramanathan, Ramesh K.
    Borad, Mitesh J.
    Tibes, Raoul
    Cohn, Allen
    Hinshaw, Ioana
    Jotte, Robert
    Rosen, Lee S.
    Hoch, Ute
    Eldon, Michael A.
    Medve, Robert
    Schroeder, Katrina
    White, Erica
    Von Hoff, Daniel D.
    CLINICAL CANCER RESEARCH, 2013, 19 (01) : 268 - 278
  • [22] A phase 1 dose escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignancies
    Hegde, Aparna
    Jayaprakash, Priyamvada
    Sumner, Elizabeth
    Di Nguyen
    Zain, Hira
    Piha-Paul, Sarina
    Karp, Daniel
    Rodon, Jordi
    Pant, Shubham
    Fu, Siqing
    Dumbrava, Ecaterina
    Yap, Timothy
    Subbiah, Vivek
    Bhosale, Priya
    Higgins, Jack
    Williams, Eric T.
    Wilson, Thomas F.
    Meric-Bernstam, Funda
    Curran, Michael
    Hong, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [23] A phase I dose escalation study with sorafenib (Sor) in combination with sirolimus (Sir) in patients (pts) with solid tumors
    van Herpen, C.
    Desar, I. M. E.
    Verijdt, R.
    van der Graaf, W. T. A.
    Timmer-Bonte, J. N. H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 130 - 130
  • [24] A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
    Greil, Richard
    Greil-Ressler, Sigrun
    Weiss, Lukas
    Schoenlieb, Charlotte
    Magnes, Teresa
    Radl, Bianca
    Bolger, Gordon T.
    Vcelar, Brigitta
    Sordillo, Peter P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 695 - 706
  • [25] Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies-results of a phase I dose-escalation study
    Blais, Normand
    Camidge, D. Ross
    Jonker, Derek J.
    Soulieres, Denis
    Laurie, Scott A.
    Diab, Sami G.
    Ruiz-Garcia, Ana
    Thall, Aron
    Zhang, Ke
    Chao, Richard C.
    Chow, Laura Q.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1487 - 1498
  • [26] Phase I/Ib dose-escalation study of aveluma in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022,
  • [27] A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors
    Ma, Yuxiang
    Fang, Wenfeng
    Zhao, Hongyun
    Bathena, Sai Praneeth
    Tendolkar, Amol
    Sheng, Jennifer
    Zhang, Li
    ONCOLOGIST, 2021, 26 (04): : E549 - E566
  • [28] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Padda, Sukhmani K.
    Krupitskaya, Yelena
    Chhatwani, Laveena
    Fisher, George A.
    Colevas, Alexander D.
    Pedro-Salcedo, Melanie San
    Decker, Rodney
    Latz, Jane E.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1013 - 1020
  • [29] A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
    Richard Greil
    Sigrun Greil-Ressler
    Lukas Weiss
    Charlotte Schönlieb
    Teresa Magnes
    Bianca Radl
    Gordon T. Bolger
    Brigitta Vcelar
    Peter P. Sordillo
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 695 - 706
  • [30] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Robert, Francisco
    Sandler, Alan
    Schiller, Joan H.
    Liu, Glenn
    Harper, Karen
    Verkh, Lev
    Huang, Xin
    Ilagan, Jennifer
    Tye, Lesley
    Chao, Richard
    Traynor, Anne M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 669 - 680
12345